Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
ISSN
09237534
Date Issued
2021
Author(s)
DOI
10.1016/j.annonc.2020.12.013
Subjects